Cardiotoxicity of Tyrosine Kinase Inhibitors: Novel Mechanisms and Implications for Atherosclerosis - Ori Ben-Yehuda

↳ This is a section part of Moment: CRT 2017: ATHEROSCLEROSIS, PHYSIOLOGY AND IMAGING - Atherosclerosis & Lipid Management

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$15.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Cardiotoxicity of Tyrosine Kinase Inhibitors: Novel Mechanisms and Implications for Atherosclerosis - Ori Ben-Yehuda  at CRT 2017.

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$15.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Cardiologists
  • Interventional Cardiologists
  • Interventional Fellows
  • Interventional Radiologists
  • Vascular Surgeons
  • Physicians with an interest in Cardiovascular Innovations

Learning Objectives

Other Components in this Moment

Overview
Where are the Guidelines Going and Should We Forget the HDL Story/CETP Inhibition? - Michael Davidson
PCSK9 Inhibitors: Review of the Clinical Trials - Why Are We So Excited? - Steven Nissen
Do PCSK9 Inhibitors Cause Cognitive Impairment? - Michael Lipinski
Cardiotoxicity of Tyrosine Kinase Inhibitors: Novel Mechanisms and Implications for Atherosclerosis - Ori Ben-Yehuda
Lipoprotein(a): Genes, Biological Role, Predictive Value and Drug Interventions - Evan Stein
Update on HDL Infusions and Atherosclerosis Regression in the ACS Patient - H. Bryan Brewer
Achieving Lipid Targets with PCSK9 Inhibition: Is Lower Always Better? - Michael Lipinski
Prospects for CV Risk Factor Reduction with PCSK9 and CETP Inhibitor Therapies - A. Michael Lincoff
Are the PCSK9 Inhibitors the Panacea of Atherosclerosis Treatment? Effects on Lipid Lowering and Beyond - Evan Stein
Update on Clinical Trials With Novel CETP Inhibitors to Raise HDL: Where Are We Today? - H. Bryan Brewer
Loading Simple Education